Search results
Feb 17, 2022 · On an adjusted basis, 2021 net income attributable to Baxter totaled $1.8 billion, or $3.61 per diluted share, an increase of 17% compared to the prior-year period. Adjusted results for full-year 2021 include a contribution to earnings of $0.08 per diluted share from Hillrom.
Feb 9, 2023 · Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the fourth quarter and full year ended Dec. 31, 2022, and provided its financial guidance for full-year and first-quarter 2023.
Feb 9, 2023 · The accompanying schedules include additional details on sales performance by product categories and segments. For full-year 2022, net income (loss) attributable to Baxter totaled ($2.4 billion), or ($4.83) per diluted share on a U.S. GAAP basis.
Find Baxter's Proxy Statement, Form 10-K filing, and Corporate Responsibility report below sorted by year.
Feb 17, 2022 · On the call this morning, we will be discussing Baxter's fourth quarter and full year 2021 financial results along with our financial outlook for 2022.
2022 Financial Outlook For full-year 2022: Baxter now expects U.S. GAAP earnings of $2.35 to $2.43 per diluted share and adjusted earnings, before special items, of $4.12 to $4.20 per diluted share. The company expects sales growth of 23% to 24% on a reported basis, 25% to 26% on a constant
People also ask
How much did Baxter make in 2022?
What was Baxter's net income in the fourth quarter?
What is Baxter's financial outlook for 2023?
What is Baxter's fourth-quarter 2021 earnings outlook?
What does Baxter expect in 2023?
How did Baxter perform in 2021?
The company’s results in 2022 and 2021 included intangible asset amortization expense of $753 million ($580 million, or $1.14 per diluted share, on an after-tax basis) and $298 million ($234 million, or $0.46 per diluted share, on an after-tax basis), respectively.
